Some interesting news out of the backyard here in Boulder, Colorado is that Nobel Prize winner Tom Cech, Ph.D. has been appointed as Special Advisor to the Morgenthaler Ventures Life Science Team, assisting Partners in the identification and review of new investment opportunities. Dr. Cech stepped down as President of the Howard Hughes Medical Institute [...]

The ‘Looking for Some (More) of This?’ series is focused upon the tracking of newly formed venture funds who are financing biomedical innovation.
There is not too much detail on this one however, it has been thinly reported that Avista Capital Partners has closed the new $1.8 billion Fund II. Taking a look at their regulatory [...]

Thank you for the wonderful (and voluminous) feedback last week, I am still working my way through all of the email responses. If you have not heard from me yet, you will shortly. Today’s posts should yield the obvious…that is there was sufficient interest and enthusiasm to warrant continuation of the Friday Communiqué series, that [...]

The ‘Looking for Some (More) of This?’ series is focused upon the tracking of newly formed venture funds who are financing biomedical innovation.
Last week OnBioVC reported on the new $550M OrbiMed Caduceus Fund IV. Today we welcome a new fund to the street that now puts 2010 newly formed capital in excess of the $1 [...]

Navigencis (Foster City, CA) a commercial-stage personalized genomics company, closed a $18M Series C financing. Participants include Procter & Gamble, Kleiner Perkins Caufield & Byers and Mohr Davidow Ventures.

Site traffic and subscribers have both been on the rise here at OnBioVC.com; we are both humbled and appreciative for this growth, and that is why now, it is important to listen to what the OnBioVC market desires as our growth trajectory is architected.
To date content at OnBioVC.com has been limited purely to details regarding [...]

OnBioVC would like to thank our sponsors, without whom complete coverage of the life science venture capital, M&A and IPO sector would not be possible:

Freestone Group | Integrated Solutions for Emerging Life Science Companies MORE INFO AT: http://www.TheFreestoneGroup.com CONTACT: Jim Lewis jlewis@thefreestonegroup.com

Regulus Pharmaceutical Consulting | Regulatory Affairs – Quality Assurance – Medical/Technical Writing – CMC [...]

Advanced Cardiac Therapeutics (Laguna Beach, CA) a development-stage electrophysiology and radiometry medical device company focused on energy delivery via catheters for cardiac ablation, closed a $5M Series b financing. Participants include NBGI Ventures.

Hot off the press! The 2009 OnBioVC Year-in-Review Trend Analysis study is available for download [HERE]; and now features OnBioIPO and OnBioM&A data too!
Bioscience venture capitalists invested $6.28 billion in 352 deals in 2009. Venture investments in 2009 represented a 3 percent increase in dollars and a 5 percent increase in deal volume from 2008. [...]

Hot off the press! The 3Q09 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $1,663M flowed into early-stage biopharma, diagnostic and device companies in the third quarter of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who you [...]

Hot off the press! The September 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $465M flowed into early-stage biopharma, diagnostic and device companies in the ninth month of 2009 and over $4,806M year-to-date! If you find the information in OnBioVC to be of value kindly forward on to colleagues who [...]

So 3Q09 is in the rear view mirror and out dribbles the August 2009 Trend Analysis - the temporal delay is indeed embarrassing however, believe it or not the September 2009 OnBioVC Trend Analysis is hot on the heels and will be available in a few days. Focusing back on August for the moment [...]

Hot off the press! (and, better late than never…) The July 2009 OnBioVC | Trend Analysis study is now available for download [HERE]. Over $668M flowed into early-stage biopharma, diagnostic and device companies in the seventh month of 2009 and over $3,821M year-to-date! If you find the information in OnBioVC to be of value kindly [...]